Sees Q3 adjusted EBITDA $26M-$30M.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYM:
- Symbiotic options imply 14.5% move in share price post-earnings
- Symbotic price target lowered to $29 from $37 at Citi
- Symbotic price target lowered to $18 from $25 at Goldman Sachs
- Symbiotic call volume above normal and directionally bullish
- Symbotic’s Expansion Stagnation and Legal Challenges Signal Potential Stock Decline